Theravance Biopharma, Inc. (TBPH) Free cash flow 2016–2025
Theravance Biopharma, Inc. (TBPH) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$238.5MFY2025 · since FY2016: -$101.1M → $238.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $238.5M | +2109.8% |
| FY2024 | -$11.9M | +59.8% |
| FY2023 | -$29.5M | +84.3% |
| FY2022 | -$187.6M | +11.2% |
| FY2021 | -$211.3M | +17.8% |
| FY2020 | -$257.0M | -6.5% |
| FY2019 | -$241.4M | -101.0% |
| FY2018 | -$120.1M | +41.0% |
| FY2017 | -$203.5M | -101.2% |
| FY2016 | -$101.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice